Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

被引：24
|
作者：
Valle, JW
Dangoor, A
Beech, J
Sherlock, DJ
Lee, SM
Scarffe, JH
Swindell, R
Ranson, M
机构：
[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[2] N Manchester Grp Hosp, Pennine Acute Hosp NHS Trust, Manchester M8 5RB, Lancs, England
[3] Middlesex Hosp, London W1T 3AA, England
[4] Lister Hosp, E&N Herts NHS Trust, Stevenage SG1 4AB, Herts, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 92卷 / 04期
关键词：
pegylated liposomal doxorubicin; hepatocellular carcinoma; phase II;
D O I：
10.1038/sj.bjc.6602394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
引用
收藏
页码：628 / 630
页数：3
相关论文
共 50 条
  • [41] Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
    Jeeyun Lee
    Joon Oh Park
    Won Seog Kim
    Se Hoon Park
    Keon Woo Park
    Moon Seok Choi
    Joon Hyoek Lee
    Kwang Cheol Koh
    Seung Woon Paik
    Byung Chul Yoo
    Jaewon Joh
    Kihyun Kim
    Chul Won Jung
    Young Suk Park
    Young-Hyuck Im
    Won Ki Kang
    Mark H. Lee
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2004, 54 : 385 - 390
  • [42] Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
    Monk, Bradley J.
    Herzog, Thomas J.
    Kaye, Stanley B.
    Krasner, Carolyn N.
    Vermorken, Jan B.
    Muggia, Franco M.
    Pujade-Lauraine, Eric
    Park, Youn C.
    Parekh, Trilok V.
    Poveda, Andres M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (15) : 2361 - 2368
  • [43] Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study
    Anne Floquet
    Adélaïde Doussau
    Véronique Brouste
    Laurent Cany
    Jean-Philippe Dutin
    Simone Mathoulin-Pélissier
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 61 - 68
  • [44] Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study
    Floquet, Anne
    Doussau, Adelaide
    Brouste, Veronique
    Cany, Laurent
    Dutin, Jean-Philippe
    Mathoulin-Pelissier, Simone
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 61 - 68
  • [45] Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma
    Wen, Xi-zhi
    Pan, Qiu-zhong
    Xu, Bu-shu
    Xiao, Wei
    Weng, De-sheng
    Zhao, Jing-jing
    Xu, Hai-rong
    Huang, Zhen
    Niu, Xiao-hui
    Zhang, Xing
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (02) : 209 - 215
  • [46] A phase II study of Caelyx™ (liposomal doxorubicin) in metastatic carcinoma of the prostate:: tolerability and efficacy modification by liposomal encapsulation
    McMenemin, R
    Macdonald, G
    Moffat, L
    Bissett, D
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) : 331 - 337
  • [47] A Phase II Study of CaelyxTM (Liposomal Doxorubicin) in Metastatic Carcinoma of the Prostate: Tolerability and Efficacy Modification by Liposomal Encapsulation
    Rhona McMenemin
    Graham Macdonald
    Leslie Moffat
    Donald Bissett
    Investigational New Drugs, 2002, 20 : 331 - 337
  • [48] Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies
    Lê, H
    Swenerton, KD
    Elit, L
    Provencher, DM
    Stuart, GCE
    Le, T
    Lee, U
    Rodgers, A
    Pond, GR
    Hu, H
    Oza, AM
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) : 799 - 806
  • [49] Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
    Philipp Harter
    Jalid Sehouli
    Rainer Kimmig
    Jörn Rau
    Felix Hilpert
    Christian Kurzeder
    Gabriele Elser
    Andreas du Bois
    Investigational New Drugs, 2013, 31 : 1499 - 1504
  • [50] Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
    Harter, Philipp
    Sehouli, Jalid
    Kimmig, Rainer
    Rau, Joern
    Hilpert, Felix
    Kurzeder, Christian
    Elser, Gabriele
    du Bois, Andreas
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1499 - 1504
12345